Shots:

• Cadila plans to launch multiple biosimilars including Bevaro in 2020 which are safe and efficacious compared to conventional treatment medicine has cleared
• The company has also cleared he USFDA inspection in Feb’20 and holds approved 16 ANDAs and currently filed 30 ANDAs  
• Bevaro is a mAb will be available in two strengths of 100 and 400 mg targeted for Ovarian Cancer- Glioblastoma Multiforme (a type of Brain cancer)- Colorectal Cancer- Breast Cancer- Lung Cancer- Cervical Cancer and Kidney Cancer in India

Ref: Cadila Pharmaceuticals | Image: Behance